Endometrial Cancer Market
Endometrial Cancer Market Size, Share & Industry Analysis, By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Hormone Therapy, Targeted Therapy), By Diagnosis (Biopsy, Imaging Tests, Blood Tests), By End User (Hospitals, Specialty Clinics, Cancer Research Institutes), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The global Endometrial Cancer Market is projected to grow at a CAGR of 7.8% from 2024 to 2031. The market value is expected to increase from USD XX in 2024 to USD YY by 2031. North America currently dominates the market, driven by advanced healthcare infrastructure and high awareness levels. Key metrics include increasing incidence of endometrial cancer, rising adoption of novel therapies, and growing focus on personalized medicine approaches.
The endometrial cancer market is rapidly expanding due to advances in diagnostic technology and the development of personalised therapeutics. The increased prevalence of risk factors such as obesity and diabetes, together with an ageing population, are important drivers of market growth. Furthermore, market growth is being driven by an expanding pipeline of novel treatments and a greater emphasis on early identification.
Endometrial Cancer Market Dynamics:
Market Trend: Shift towards minimally invasive surgical techniques and robotic-assisted procedures
The endometrial cancer treatment landscape is quickly shifting towards minimally invasive surgical approaches and robotic-assisted procedures. This movement is motivated by the advantages of these procedures, which include shorter hospital stays, less discomfort, faster recovery times, and better cosmetic results. Robotic surgery, in particular, is becoming increasingly popular due to its accuracy and capacity to do difficult treatments with minimal invasiveness.
For example, the da Vinci Surgical System, which is commonly utilised in gynaecologic oncology operations, has demonstrated promising results in endometrial cancer surgery. A research published in the Journal of Robotic Surgery in 2023 found that robotic-assisted hysterectomy for endometrial cancer resulted in a 30% reduction in postoperative complications when compared to traditional open surgery.
Additionally, the use of sentinel lymph node mapping techniques for endometrial cancer staging has grown. This method enables for more targeted lymph node inspection, potentially minimising the need for extensive lymphadenectomy and its associated complications. Sentinel lymph node mapping is now recommended by the Society of Gynaecologic Oncology as part of the standard of care for early-stage endometrial cancer at numerous hospitals.
Market Driver: Increasing incidence of endometrial cancer and growing awareness about early detection
The increasing prevalence of endometrial cancer is a major driver of the endometrial cancer market. According to the World Cancer Research Fund, endometrial cancer is the sixth most frequent disease among women worldwide, with an estimated 417,000 new cases in 2020. This growing disease burden has led an increase in research efforts to create more effective diagnostic tools and treatment choices.
Awareness campaigns emphasising the need of early detection have also helped drive market expansion. Endometrial cancer, unlike certain other gynaecological tumours, usually manifests with early symptoms such as irregular vaginal bleeding, which can lead to an earlier diagnosis if detected. For example, the Foundation for Women's Cancer reported a 15% rise in inquiry about endometrial cancer symptoms and screening options in 2022 over the previous year.
Furthermore, advances in diagnostic methods, such as enhanced imaging techniques and the identification of novel biomarkers, have improved the capacity to detect endometrial cancer early on. According to our analysis, the global endometrial cancer diagnostics market will be worth $YY billion by 2023, expanding at an 8.2% CAGR between 2023 and 2031.
Market Restraint: Side effects and high costs associated with advanced treatment modalities
The use of complicated therapeutic approaches in endometrial cancer is hampered by side effects and high costs. While innovative drugs like targeted pharmaceuticals and immunotherapies have the potential to improve outcomes, they can also cause serious side effects and financial hardship for patients.
PARP inhibitors, while promising in the treatment of certain kinds of endometrial cancer, can cause fatigue, nausea, and bone marrow suppression. These adverse effects might have an influence on patients' quality of life, leading to therapy cessation in some situations. According to a study published in the Journal of Clinical Oncology, around 25% of patients treated with PARP inhibitors for gynaecologic malignancies had grade 3 or higher side effects.
Furthermore, the cost of these modern treatments may be high. According to an American Cancer Society survey, the average monthly cost of targeted therapies for gynaecologic tumours exceeded $10,000, with certain treatments costing more than $20,000. This high cost may restrict access to some treatments, especially in areas with limited healthcare resources or inadequate insurance coverage.
Segment Overview:
By treatment type, surgery category dominates the endometrial cancer market
Surgery holds the biggest market share in the Endometrial Cancer Market since it is the primary treatment option for the vast majority of endometrial cancer patients. This segment's dominance can be linked to the effectiveness of surgical treatments in tumour removal and disease staging, which is critical for designing future treatment strategies.
Recent developments in surgical techniques have centred on minimally invasive procedures that yield superior results. For example, in 2023, a well-known medical equipment business introduced a complicated laparoscopic system created exclusively for gynaecologic oncology treatments, which improved vision and precision. These advancements have aided the segment's expansion, with our research estimating that the global market for gynaecologic surgery instruments will be worth $YY billion by 2031.
The oncology community is constantly developing surgical methods for endometrial cancer, with a greater emphasis on adapting the scope of operation to specific patient needs and tumour characteristics. The increased use of sentinel lymph node biopsy techniques has resulted in more targeted lymph node evaluation, potentially reducing the morbidity associated with massive lymphadenectomy. The National Comprehensive Cancer Network has endorsed sentinel lymph node mapping as a surgical staging alternative for evident uterine-confined endometrial cancer.
Regional Outlook:
North America dominates the Endometrial Cancer Market, holding the largest market share.
North America's dominance in the Endometrial Cancer Market is mostly attributable to its advanced healthcare infrastructure, high healthcare spending, and large number of important market competitors. The region's dominance is bolstered by favourable reimbursement regulations and a strong pipeline of endometrial cancer treatments.
Endometrial cancer research and treatment are well advanced in the United States. on fiscal year 2022, the National Cancer Institute will invest more than $100 million on endometrial cancer research, including clinical trials and novel treatment methods.
Recent cooperation between academic institutions and pharmaceutical corporations have hastened the development of novel medicines. For example, in 2023, a major cancer centre in the United States collaborated with a leading biotech company to create a personalised neoantigen vaccine for endometrial cancer using sophisticated genomics and immunotherapy technologies.
The region has also seen an increase in the use of molecular profiling for endometrial cancer, with an expected 60% of newly diagnosed cases receiving a thorough genomic profile by 2022. This breakthrough has considerably enhanced the overall endometrial cancer market in the region by allowing for more customised treatment options.
Competitive Intelligence:
The Endometrial Cancer Market is characterised by fierce competition among major players, with an emphasis on developing new medicines and growing product portfolios. Leading companies are investing heavily in R&D to develop more effective and focused treatments. AstraZeneca plc holds a sizable market share thanks to its strong presence in the PARP inhibitor market with Lynparza (olaparib), which has showed promise in a number of endometrial malignancies. Lynparza's income climbed by 22% in 2022, thanks in part to its increased use in gynaecological tumours.
Merck & Co., Inc. has improved its market position with the success of Keytruda (pembrolizumab), an immunotherapy medicine used to treat advanced endometrial cancer. In 2023, the company intends to conduct a phase III trial of Keytruda in combination with standard-of-care therapy for early-stage endometrial cancer, which might expand its market reach. GlaxoSmithKline plc has concentrated on creating tailored drugs, such as Zejula (niraparib), a PARP inhibitor being tested for endometrial cancer.
Eisai Co., Ltd. and Karyopharm Therapeutics are moving forward with novel drug development initiatives that target particular molecular pathways in endometrial cancer. The industry has also seen a rise in strategic agreements between pharmaceutical companies and diagnostic organisations to produce companion diagnostics for specific treatments.
Future market growth is likely to be fuelled by the discovery of new immunotherapies, the advancement of precision medicine technologies, and the launch of combination medicines that target several pathways. Companies that invest in these areas will gain a competitive advantage in the emerging market landscape.
Analyst Opinion:
The Endometrial Cancer Market is expected to expand fast, driven by the disease's increasing prevalence and the introduction of more customised treatment methods. The application of molecular profiling and artificial intelligence in medical decision-making is predicted to improve patient care, potentially leading to better outcomes and less expensive treatments.
The development of liquid biopsy devices for the early detection and monitoring of endometrial cancer is an important trend to watch. These noninvasive assays have the potential to change the diagnostic landscape, allowing for earlier interventions and more precise therapy monitoring.
Major Players:
-
AstraZeneca plc
-
Merck & Co., Inc.
-
GlaxoSmithKline plc
-
Novartis AG
-
Roche Holding AG
-
Eisai Co., Ltd.
-
Takeda Pharmaceutical Company Limited
-
Johnson & Johnson
-
Pfizer Inc.
-
Karyopharm Therapeutics
Key Developments:
-
In April 2023, AstraZeneca and Merck & Co. reported good findings from a Phase III trial combining Lynparza and Keytruda in advanced endometrial cancer patients with particular genetic abnormalities.
-
GlaxoSmithKline will launch a Phase II trial of a new antibody-drug combination in August 2023 to treat HER2-positive endometrial cancer.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. AstraZeneca plc
5.2. Merck & Co., Inc.
5.3. GlaxoSmithKline plc
5.4. Novartis AG
5.5. Roche Holding AG
5.6. Eisai Co., Ltd.
5.7. Takeda Pharmaceutical Company Limited
5.8. Johnson & Johnson
5.9. Pfizer Inc.
5.10. Karyopharm Therapeutics (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards minimally invasive surgical techniques and robotic-assisted procedures
6.1.2. Integration of molecular profiling and AI in treatment decision-making
6.1.3. Development of liquid biopsy technologies for early detection and monitoring
6.2. Market Drivers
6.2.1. Increasing incidence of endometrial cancer and growing awareness about early detection
6.2.2. Advancements in targeted therapies and immunotherapies
6.2.3. Rising adoption of precision medicine approaches in oncology
6.3. Market Restraints
6.3.1. Side effects and high costs associated with advanced treatment modalities
6.3.2. Challenges in treating advanced and recurrent endometrial cancer
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TREATMENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Surgery
7.1.1. Hysterectomy
7.1.2. Lymphadenectomy
7.1.3. Sentinel Lymph Node Mapping
7.2. Radiation Therapy
7.2.1. External Beam Radiation
7.2.2. Brachytherapy
7.3. Chemotherapy
7.3.1. Platinum-based Chemotherapy
7.3.2. Taxane-based Chemotherapy
7.4. Hormone Therapy
7.4.1. Progestins
7.4.2. Aromatase Inhibitors
7.5. Targeted Therapy
7.5.1. PARP Inhibitors
7.5.2. mTOR Inhibitors
7.5.3. Immunotherapy
8. BY DIAGNOSIS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Biopsy
8.1.1. Endometrial Biopsy
8.1.2. Hysteroscopy with Biopsy
8.2. Imaging Tests
8.2.1. Transvaginal Ultrasound
8.2.2. CT Scan
8.2.3. MRI
8.2.4. PET Scan
8.3. Blood Tests
8.3.1. CA-125 Test
8.3.2. Complete Blood Count
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospitals
9.1.1. Public Hospitals
9.1.2. Private Hospitals
9.2. Specialty Clinics
9.3. Cancer Research Institutes
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Treatment Type:
-
Surgery
-
Radiation Therapy
-
Chemotherapy
-
Hormone Therapy
-
Targeted Therapy
By Diagnosis:
-
Biopsy
-
Imaging Tests
-
Blood Tests
By End User:
-
Hospitals
-
Specialty Clinics
-
Cancer Research Institutes
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511